• database Web of Science indexed

Canada · Multidisciplinary Digital Pu...

workspace_premium Q2 — Oncology lock Subscription

Current Oncology

Current Oncology is a journal indexed in SJR in Oncology with an H index of 55. It has a price of 2100 €. It has a best quartile of Q2. It is published in English.

ISSN: 1198-0052

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

Category: Oncology

Indexation: verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

NPD Q2

H-index 55

Acceptance rate pie_chart

29% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.100 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Web of Science

SJR Impact

—

H-index

Docs (year)

455

Docs 3y

484

Total refs

19553

Cites 3y

1558

Citable 3y

433

Cites/Doc 2y

2.63

Ref/Doc

42.97

Immediate OA

2100 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Benefits, issues, and recommendations for personalized medicine in oncology in Canada

What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer?

Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group

Comparing enrolees with non-enrolees of cancer-patient navigation at end of life

Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites

Chemotherapy-induced small bowel perforation in a patient with extra-pulmonary small cell carcinoma of the small bowel: A case report.

Challenging obesity relating to Barrett esophagitis

Cancer nutrition rehabilitation program: the role of social work

Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis

CANCER AND THROMBOSIS: RECENT ADVANCES

Canadian recommendations for the management of breakthrough cancer pain

Breast cancer screening policy - good science should trump bad politics

SHOW MORE ARTICLES

BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults

Balancing potential quality-of-life benefits against the risk of lethal late recurrence with bladder-preserving surgery

Author Index

Arterial occlusion precipitated by cisplatin-based chemotherapy

Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study

An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction

African-Caribbean Cancer Consortium Scientific and Training Conference 2017rence 2017 Meeting Report

Adjuvant interferon alfa for melanoma

Active treatment in low-risk prostate cancer: a population-based study

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

A primer on the genetics of medullary thyroid cancer

FAQs

SJR is not available (NPD) for Current Oncology in the CountryOfPapers database.

Immediate OA APC is 2100 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Current Oncology is 29%.

Current Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Current Oncology?

What is the APC / publication cost?

What is the acceptance rate?